[胰高血糖素样肽-1受体激动剂用于治疗心力衰竭患者？：STEP-HFpEF和STEP-HFpEF糖尿病研究] - Suppr

Suppr

超能文献

[GLP-1 receptor agonists for the treatment of patients with heart failure? : STEP-HFpEF and STEP-HFpEF DM].

作者信息

Schröder Sophie Charlotte, Laufs Ulrich, Nitschmann Sirka

机构信息

Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Deutschland.

, Lippetal, Deutschland.

出版信息

Inn Med (Heidelb). 2024 Oct;65(10):1044-1047. doi: 10.1007/s00108-024-01763-7. Epub 2024 Aug 28.

DOI:10.1007/s00108-024-01763-7

PMID:39196356

Abstract

摘要

相似文献

[GLP-1 receptor agonists for the treatment of patients with heart failure? : STEP-HFpEF and STEP-HFpEF DM].[胰高血糖素样肽-1受体激动剂用于治疗心力衰竭患者？：STEP-HFpEF和STEP-HFpEF糖尿病研究]

Inn Med (Heidelb). 2024 Oct;65(10):1044-1047. doi: 10.1007/s00108-024-01763-7. Epub 2024 Aug 28.

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.司美格鲁肽对比安慰剂在射血分数轻度降低或保留的心衰患者中的疗效：SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 随机试验的汇总分析。

Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.

Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.比较胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂对糖尿病合并射血分数保留心力衰竭患者的影响：一项荟萃分析。

Cardiovasc Diabetol. 2024 Aug 31;23(1):324. doi: 10.1186/s12933-024-02415-8.

Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.肥胖、射血分数保留的心力衰竭和胰高血糖素样肽-1 受体激动剂的作用。

ESC Heart Fail. 2024 Apr;11(2):649-661. doi: 10.1002/ehf2.14560. Epub 2023 Dec 13.

Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?SELECT试验是否能让我们放心地在射血分数降低的心力衰竭（HFrEF）中使用胰高血糖素样肽-1（GLP-1）受体激动剂？

J Am Coll Cardiol. 2024 Sep 17;84(12):1119-1122. doi: 10.1016/j.jacc.2024.06.026. Epub 2024 Aug 7.

New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.利用胰高血糖素样肽-1受体激动剂（GLP-1 RA）预防代谢综合征和2型糖尿病中射血分数保留的心力衰竭的新机制：综述

Int J Mol Sci. 2024 Apr 17;25(8):4407. doi: 10.3390/ijms25084407.

Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.胰高血糖素样肽-1 受体激动剂 (GLP-1RA) 对心脏结构和功能的影响：一项随机对照试验的系统评价和荟萃分析。

Cardiovasc Drugs Ther. 2024 Apr;38(2):371-389. doi: 10.1007/s10557-022-07360-w. Epub 2022 Jul 12.

Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure.胰高血糖素样肽-1受体激动剂在心力衰竭全谱中的应用

J Clin Endocrinol Metab. 2023 Dec 21;109(1):4-9. doi: 10.1210/clinem/dgad398.

Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.胰高血糖素样肽-1 受体激动剂在心力衰竭和 2 型糖尿病中的使用及其与结局的相关性：来自瑞典心力衰竭和瑞典国家糖尿病登记处的数据。

Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):296-306. doi: 10.1093/ehjcvp/pvae026.

Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的心力衰竭：随机和观察性研究的系统评价与荟萃分析

BMC Cardiovasc Disord. 2016 May 11;16:91. doi: 10.1186/s12872-016-0260-0.

本文引用的文献

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。

N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.司美格鲁肽在肥胖症分级和体重减轻的 HFpEF 中的应用：STEP-HFpEF 试验的预设分析。

Nat Med. 2023 Sep;29(9):2358-2365. doi: 10.1038/s41591-023-02526-x. Epub 2023 Aug 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验